washingtonpost.com  > Print Edition > Nation and Politics
Correction to This Article
A Jan. 20 article on Medicare's decision to expand its coverage of implantable defibrillators misstated the condition the device is intended to correct. The condition is ventricular fibrillation, not ventricular defibrillation.

Medicare To Cover Cardiac Device

Plan Raises Issue Of Line Between Care and Research

By Rick Weiss
Washington Post Staff Writer
Thursday, January 20, 2005; Page A01

The government has decided to expand its coverage for surgically implanted heart-shocking devices for people with weakened hearts, in what could be the most expensive single decision in Medicare's history, federal officials said yesterday.

More than half a million Americans with the progressive heart-weakening condition known as congestive heart failure could be eligible for the battery-powered implants and accompanying surgery under the plan, which Medicare officials said they will roll out in the next week or so.

_____Medicare Legislation_____
Special Report: Full Coverage

The devices, known as implantable cardioverter-defibrillators, or ICDs, sense heart rhythm abnormalities and deliver shocks to the heart when potentially fatal flutters occur.

The Medicare decision, however, will be significant for more than its cost, which officials said yesterday could be about $3 billion a year. It also represents the most aggressive effort yet to use the federal insurance plan for the elderly as a backdoor way to learn more about what works and what does not in medicine.

As a condition of coverage, Medicare will insist on collecting ongoing information about patients' health, which may help the program decide over time whether ICDs help certain types of patients.

The plan is part of an evolving federal effort to prevent a replay of recent events in which physicians and patients were surprised to learn that some popular anti-inflammatory drugs and antidepressants have more side effects than previously recognized. Given the huge numbers of patients who receive drugs and medical devices through Medicare, officials said, long-term data collection by the program can be a powerful complement to the modest follow-up efforts made by manufacturers and the Food and Drug Administration.

"Hopefully this will both ensure that patients get the best care as quickly as possible and also we'll continue to get smarter and learn more about unanticipated safety problems and how to use these technologies most effectively," said Sean Tunis, chief clinical officer at the Centers for Medicare and Medicaid Services.

Medicare has covered ICDs mostly for patients who had already suffered potentially fatal disturbances in their heart rhythms. But officials decided to expand the coverage because of new evidence that ICDs can save the lives of many people who are at increased risk for such episodes but have not yet suffered them.

The plan to collect long-term data raises subtle questions about the line between medical care and research. It is unethical under federal and international human research guidelines to demand participation in research as a condition of receiving medical care. While Medicare always requires some medical information from patients to ensure eligibility, experts in medical ethics said expanded efforts to peg coverage to data collection would have to be watched closely to ensure they do not cross the line.

Issues of cost also loom large -- especially amid concerns over Medicare's fiscal condition, given skyrocketing health care costs and the aging population. An analysis conducted by Duke University researchers found that, at about $30,000 for the device and the surgery, coverage for patients with mild to moderate congestive heart failure would be at least as cost-effective as other coverage Medicare typically offers -- even counting the fact that up to 80 percent of implanted patients are expected to never need a shock.

But those estimates look only at how much it costs to give a patient an extra year of high-quality life, not at the cost to society overall. If just 20 percent of eligible patients got the devices -- the percentage of use among patients eligible for current defibrillator treatments -- it would cost the government about $3 billion a year. Full participation could cost $15 billion or more.

That would be about equal to all other outpatient Medicare expenditures combined.

"Because the number of people can be huge, the effect on the system can be enormous," said Ezekiel Emanuel, chairman of the department of clinical bioethics at the National Institutes of Health. "That's an issue we haven't been able to grapple with very well. How do you set priorities?"

The coverage decision coincides with today's publication, in the New England Journal of Medicine, of results from a major study of ICDs sponsored by the National Institutes of Health.


CONTINUED    1 2    Next >

© 2005 The Washington Post Company